I
n the late 19th century, William Osler notoriously quipped that treating infants with cardiac defects was futile, thereby encouraging Maude Abbott to pursue her rigorous studies of pathologic heart specimens. Ultimately, this work resulted in The Atlas of Congenital Cardiac Disease, which is widely regarded as the first systematic catalogue of cardiovascular malformation (CVM) and therefore the first classification system for clinical pediatric cardiology. Organizing malformations requires consideration of cause. The investigations of the etiology of CVM, also known as congenital heart disease (CHD), has advanced on 2 largely independent lines of thought: environmental or genetic. 1, 2 During the same time, the advent and rapid evolution of surgical intervention for these conditions defined an exquisite clinical taxonomy that was based on anatomy and physiology. 3 Only recently have there been efforts to reconcile environmental and genetic factors in a clinically meaningful manner and integrate this information into the existing classification scheme. Classification schemes for CVM continue to present significant challenges for both clinicians and researchers. When considering cause, it is important to group lesions appropriately and avoid misclassification that may confound interpretation. To this end, classification paradigms have been developed that account for the developmental relationships of lesions, in addition to the anatomic relationships previously described, to increase confidence in grouping. 4 The National Birth Defects Prevention Study developed an exhaustive taxonomy that organizes CVM in multiple ways, including the most specific definition of a single defect (eg, hypoplastic left heart syndrome-the so-called "splitting" approach), the most broad groupings (eg, left sided outflow tract obstruction lesions-the "clumping" approach), and an intermediate level that allows flexibility with the analysis of common associations (eg, aortic stenosis and coarctation of the aorta). (hypertension, infection, gestational diabetes). Among several positive findings, some of which confirm established associations, some are either new or of general interest. For example, the association between increased paternal age and CVM was only seen in children with genetic abnormalities, suggesting the environmental factor is a risk for genetic abnormalities that may include CVM, but in the absence of a genetic abnormality may not pose an additional risk. Interestingly, in the present study, smoking during early pregnancy was associated with an increased risk of CVM (OR 2.0 [1.2 to 3.5], P=0.0004), the relative risk consistent with previous studies. Since smoking is common and modifiable, it is a good target for intervention, 8 but causality has not been established like it has for smoking's adverse impact on fetal growth, in part due to several studies that have shown no association. Interestingly, it was noted that there has been a significant decrease in maternal smoking recently, suggesting it may be possible to identify the impact of smoking cessation on CVM in the near future. Environmental risk factors include over-the-counter, prescription, and fertility medications. The sensational example of thalidomide was followed by the evaluation of numerous medications as potential causes of CVM, including recently bupropion, 9 which resulted in the significant reclassification of the medication's pregnancy risk profile from Category C to Category D by the Food and Drug Administration. Weak associations are difficult to interpret because they may represent true risk or false association. Interpreting epidemiologic data requires an understanding of the strengths and weaknesses of the case-control study design. Most importantly, association does not prove causation, and spurious associations may result for a number of reasons, including recall bias, resulting in conflicting or inconsistent findings. The current study's observation that maternal drug use during pregnancy is increasing underscores the importance of understanding the safety of commonly used drugs. There have been instances where a drug is considered a risk based on early epidemiologic evidence and that risk is later determined to be incorrect, raising questions about what the level of proof should be in this context. For example, lithium was shown to be associated with CVM, in particular Ebstein anomaly of the tricuspid valve, but after more analyses this collective position was reversed. So, while the possibility of lithium teratogenicity has not been excluded, the inconsistency in results undermined the confidence in a possible small risk and ultimately became a cautionary tale for association studies in pediatric cardiology. 10, 11 Bradford Hill reported a seminal approach to examining causation in the context of association that includes a rigorous assessment of several criteria, including strength of association, temporality, consistency, biological plausibility, coherence and analogy, a dose-response, and experimental support of mechanism.
12 These considerations will be helpful in the ongoing assessment of the potential adverse effects of specific medications that may be associated with CVM. Fung et al described several interesting observations pertaining to genetic risk factors. Importantly, the family history was demonstrated to be the most reliable tool in establishing risk. Genetic testing increased significantly from 9% to 25% from 1990 to 2011, and while the overall yield was only 10%, if there was a positive family history or the presence of an extracardiac anomaly, then the yield increased to 32% and 43%, respectively. Recently, genetic testing patterns between geneticists and cardiologists were explored in a cohort of CVM patients, identifying inconsistencies about perceived indications for testing and the need for a systematic approach clinically as well as larger, more robust research studies that combine careful phenotyping with genetic and environmental factors. 13 Taken together, these observations emphasize the fact that while there is significant evidence that most CVM has a genetic component, we are only able to identify a small proportion of genetic causes presently. Identifiable single-gene mutations account for a small minority of cases and indications to screen specific genes are limited. As more causes are identified and sequencing technology advances, the ability to identify complex or polygenic disorders like nonsyndromic sporadic CVM will improve. In addition, these technologies will provide insight into gene-gene and gene-environment interactions. Increasingly, networks of genetic modifiers will be elucidated that better define genetic risk. For example, the Pediatric Heart Network identified single nucleotide polymorphisms (SNPs) in 5 genes within the Renin-Angiotensin-Aldosterone system that predict failure of normal postoperative remodeling as well as poor somatic growth, suggesting that the presence of these variants may predict adverse outcome and therefore identify a subset of patients at relatively high risk.
14 This approach on a broad scale may resemble a comprehensive risk profile for all types of CVM, much like newborn screening. Advances in personalized medicine are already leveraging the clinical utility of genetic information to identify specific risks in specific people, 15 suggesting that we are quickly approaching a paradigm shift in preventive management. There is ample evidence that nonsyndromic CVM is polygenic, and gene-gene and gene-environment interactions will play a significant role in pathogenesis. [16] [17] [18] The involvement of multiple factors presents challenges for assessing risk and defining predisposition. Classically, a genetic predisposition involving one or more genetic abnormalities is followed by an environmental insult where both types of factors are required for disease manifestation. Little is known at present about how this paradigm might be applied to CVM. Accordingly, the authors call for a more rigorous ascertainment of both genetic and environmental risk factors, including gene-environment interactions that contribute to CVM. This might translate to a systematic approach that incorporates all of these factors in electronic medical record and data registries for clinical use and multisite research. As more is learned about the genetic basis of CVM and the impact of environmental factors, composite risk profiles that capture both genetic and environmental factors may allow the development of clinically useful thresholds. As the authors explain, these advances will facilitate our ability to implement prevention and early risk stratification and prevention strategies through improved diagnostic testing, as well as more effective early intervention and targeted therapeutic plans through improved patient-specific risk definition.
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